Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acumen Pharmaceuticals Inc
NASDAQ ABOS
Data sourced from
and
and
Acumen Pharmaceuticals Inc Capital Stock Change 1 year YoY Change (%) for the year ending December 31, 2023: 3,225.05%
Acumen Pharmaceuticals Inc Capital Stock Change 1 year YoY Change (%) is 3,225.05% for the year ending December 31, 2023, a 3,387.83% change year over year. Capital Stock Change is the net change in the company's capital stock during a specific period, including the issuance or retirement of shares. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
-
Acumen Pharmaceuticals Inc Capital Stock Change for the year ending December 31, 2022 was USD 3.79 M, a -98.09% change year over year.
-
Acumen Pharmaceuticals Inc Capital Stock Change for the year ending December 31, 2021 was USD 198.59 M, a 344.51% change year over year.
-
Acumen Pharmaceuticals Inc Capital Stock Change for the year ending December 31, 2020 was USD 44.67 M, a 616.86% change year over year.
-
Acumen Pharmaceuticals Inc Capital Stock Change for the year ending December 31, 2019 was USD 6.23 M.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ABOS
| CEO | Mr. Daniel J. O'Connell M.B.A. |
| IPO Date | July 1, 2021 |
| Location | United States |
| Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email